Aspirin Use May Help Hospitalized COVID-19 Patients
After less than one year of focused scientific research on Coronavirus disease-2019 (COVID-19), it is thought that COVID-19 is associated with hypercoagulability and increased thrombotic risk in critically ill patients. Researchers in Maryland, USA conducted a retrospective, observational cohort study of adult patients admitted with COVID-19 to multiple hospitals in the United States between March 2020 and July 2020. Four hundred twelve patients were included in the study. The primary outcome evaluated was the need for mechanical ventilation, while the secondary outcomes were ICU admission and in-hospital mortality. Results showed that three hundred fourteen patients (76.3%) did not receive aspirin, while 98 patients (23.7%) received aspirin within 24 hours of admission or 7 days prior to admission. It was also clear that aspirin use had a solid association with less mechanical ventilation (35.7% aspirin vs. 48.4% non-aspirin, p=0.03) and ICU admission (38.8% aspirin vs. 51.0% non-aspirin, p=0.04), but no crude association with in-hospital mortality (26.5% aspirin vs. 23.2% non-aspirin, p=0.51). There were also no differences in major bleeding (p=0.69) or overt thrombosis (p=0.82) between aspirin and non-aspirin users. Researchers concluded that aspirin use may be associated with improved outcomes in hospitalized COVID-19 patients, however, a powerful randomized controlled trial is needed to assess whether a causal relationship exists between aspirin use versus reduced lung injury and mortality in COVID-19 patients.
Source: 1. Chow, Jonathan H. et al. “Aspirin Use Is Associated with Decreased Mechanical Ventilation, ICU Admission, And In-Hospital Mortality In Hospitalized Patients With COVID-19”. Anesthesia & Analgesia, Oct 2020. Ovid Technologies (Wolters Kluwer Health), doi:10.1213/ane.0000000000005292. Accessed 8 Nov 2020.